Ipsen SA's business model revolves around the development, manufacturing, and commercialization of innovative pharmaceutical products for various therapeutic areas. As a global biopharmaceutical company, Ipsen focuses on specialty care and oncology, offering a diverse portfolio of drugs to address unmet medical needs. They aim to improve patients' lives through effective treatments, cutting-edge research, and collaborations with healthcare professionals. Ipsen's commitment to innovation and patient-centric solutions further strengthens their foothold in the pharmaceutical industry.

Ipsen SA is primarily active in the pharmaceutical industry.

The main competitors of Ipsen SA in the market include companies such as Novartis, Sanofi, and Merck KGaA.

Ipsen SA is a renowned pharmaceutical company with a rich history and background. Founded in 1929, Ipsen has grown to become a global leader in specialty care treatments for urology, oncology, and endocrinology. With a strong focus on innovation and research, Ipsen has developed a diverse range of products to address various medical needs. Over the years, the company has expanded its reach to more than 115 countries and collaborates with numerous partners to enhance patient care worldwide. Ipsen's commitment to improving patient outcomes through cutting-edge therapies and its global presence has solidified its position as a trusted name in the pharmaceutical industry.

Some significant milestones achieved by Ipsen SA include the acquisition of Clementia Pharmaceuticals in 2019, expanding its rare diseases portfolio, and the FDA approval of Cabometyx for advanced hepatocellular carcinoma in 2018. Ipsen SA has also made advancements in neurology, with the 2019 FDA approval of Dysport for pediatric lower limb spasticity. Furthermore, Ipsen SA has collaborated with partners to develop innovative treatments, such as the partnership with Exelixis for the development of Cabometyx. These milestones highlight Ipsen SA's commitment to research, development, and expanding treatment options in various therapeutic areas.

Ipsen SA is primarily present in various countries and regions globally. The company has a strong presence in Europe, with its headquarters based in France. Ipsen also has significant operations in the United States and several other countries across North and South America, including Canada and Brazil. Additionally, Ipsen has a growing presence in Asia, particularly in China and Japan, as well as key markets in the Middle East and Africa. With its widespread footprint, Ipsen SA aims to serve patients and healthcare professionals across multiple regions and provide its pharmaceutical solutions to a diverse and global community.

Analysts currently set an average price target of 135,82 EUR for the Ipsen stock (median: 132,60 EUR), implying −18,8 % versus the latest price. The consensus is based on 19 analyst ratings.

Ipsen Analyytikkojen kursstavoitteet 2026

19 analysts currently rate the Ipsen stock: 8 recommend buying, 9 holding and 2 selling. For 2026, analysts expect Ipsen to generate revenue of 4,39 Mrd. EUR and earnings per share of 15,49 EUR.

Ipsen Analyytikkojen kursstavoitteet 2026

The Ipsen share (IPN.PA) is listed on 8 stock exchanges, including: Frankfurt (I7G.F), München (I7G.MU), Düsseldorf (I7G.DU), London (0MH6.L), Wien (IPN.VI), Paris (IPN.PA).

Ipsen SA is a global pharmaceutical company based in Paris, France. The company specializes in the research, development, manufacturing, and marketing of medications used to treat cancer, neurological diseases, and rare diseases. Ipsen offers a wide range of products divided into three main business areas. 1. Oncology In the field of oncology, Ipsen offers therapies for the treatment of neuroendocrine tumors (NET), prostate cancer, and pancreatic cancer. The company also has a promising pipeline of medications for the treatment of various types of cancer. 2. Neuroscience Ipsen is a leading provider of therapies for the treatment of neurological diseases such as spasticity, cerebral palsy, and migraines. Products in this area include Dysport, an injectable botulinum toxin, as well as numerous other orally-administered medications. 3. Rare Diseases Ipsen has also specialized in the development and marketing of therapies for the treatment of rare diseases. Products in this area include Somatuline for the treatment of acromegaly and neuroendocrine tumors, as well as Increlex for the treatment of short stature. In addition, Ipsen has a strong presence in Europe, North America, and the Asia-Pacific region. The company has built a large network of subsidiaries, distribution partners, and licensees that allows it to market its products worldwide. Ipsen also relies on innovative partnerships and strategic acquisitions to strengthen its market presence. In 2020, the company acquired Clementia Pharmaceuticals, a company specializing in the development of therapies for the treatment of rare bone diseases such as fibrodysplasia ossificans progressiva (FOP). Overall, Ipsen's business model is based on a strong research and development department that focuses on identifying new therapies and improving existing treatment options. The company works closely with medical professionals, academic institutions, and other industry partners. Ipsen also strives for sustainable corporate development by focusing on environmentally-friendly practices and ethical business practices. The company is committed to carbon-neutral production and supports social projects worldwide. Overall, Ipsen has built a robust business model supported by its strong presence in the global market, its products in various therapy areas, and its innovative research and development department.

odotettu liikevaihto Ipsen on 4,39 Mrd. EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Ipsen on 1,27 Mrd. EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Ipsen:n hinta-voitto-suhde (P/E) on tällä hetkellä 10,55. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Ipsen-osakkeen arvostusta.

Ipsen:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,06. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Ipsen-osakkeen arvostuskennuslukuna.

Ipsen:n Eulpool-laatuscore on 5/10.

Ipsen:n ISIN on FR0010259150. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Ipsen:n WKN on A0ESMG. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Ipsen:n ticker on IPN.PA. Tämä pörssinoteeraus käytetään Ipsen-osakkeiden kauppaan pörssissä.

Viimeisten 12 kuukauden aikana Ipsen maksoi osinkoa 1,40 EUR . Tämä vastaa osingontuottoa noin 0,86 %. Tulevien 12 kuukauden aikana Ipsen odotetaan maksavan osinkoa 1,60 EUR.

Ipsen:n nykyinen osinkotuotto on 0,86 %.

Ipsen maksaa osinkoa, joka jaetaan kuukausina , , , .

Ipsen maksoi osinkoa joka vuosi viimeisten 20 vuoden aikana.

Tulevien 12 kuukauden aikana odotetaan osinkoja, joiden määrä on 1,60 EUR. Tämä vastaa osingontuottoa 0,96 %.

Ipsen kuuluu sektoriin 'Terveydenhuolto'.

Saadaksesi viimeisen osingon Ipsen:sta päivältä määrässä 1,4 EUR, sinulla piti olla osake portfoliossasi ennen irtoamispäivää .

Viimeinen osinko maksettiin .

Vuonna 2025 Ipsen jakoi 1,2 EUR osinkona.

Ipsen:n osingot jaetaan valuutassa EUR.